Today: 7 February 2026
Subscribe
Browse Category

NYSE:EPD News 7 December 2025 - 4 January 2026

Energy Transfer stock today: ET ends 2026’s first session higher as LNG export record keeps gas flows in focus

Energy Transfer stock today: ET ends 2026’s first session higher as LNG export record keeps gas flows in focus

NEW YORK, Jan 3, 2026, 17:45 ET — Market closed Energy Transfer LP’s U.S.-listed units closed 0.6% higher at $16.59 on Friday, the first trading day of 2026, as energy infrastructure names started the year on firmer footing. The move matters now because the midstream group is being pulled between two macro forces: accelerating U.S. gas demand tied to LNG exports and shifting expectations for interest rates. Pipeline operators make money moving volumes, and the market is looking for proof that U.S. natural gas demand can stay strong into 2026. Reuters Rates remain the other key cross-current. U.S. Treasury yields
4 January 2026
·······
EPD Stock Today (December 7, 2025): Enterprise Products Partners’ 6.7% Yield, JPMorgan Downgrade and Bahia Pipeline Deal Shape 2026 Outlook

EPD Stock Today (December 7, 2025): Enterprise Products Partners’ 6.7% Yield, JPMorgan Downgrade and Bahia Pipeline Deal Shape 2026 Outlook

Enterprise Products Partners L.P. (NYSE: EPD) remains one of the most closely watched high-yield income plays in the energy sector as of December 7, 2025. Its units are trading a little above $32, offering investors a distribution yield of roughly 6.7–6.8%, supported by long-lived midstream infrastructure and a multi‑billion‑dollar growth pipeline. MarketBeat+1 At the same time, fresh developments – including a JPMorgan downgrade, a major pipeline joint venture with ExxonMobil, ongoing buybacks and a recent acquisition in the Permian Basin – are reshaping how analysts and algorithms are valuing EPD stock heading into 2026. Pulse 2.0+3Investing.com+3Business Wire+3 Where EPD Stock
7 December 2025
·····

Stock Market Today

GSK share price set for Monday watch after EU clears Nucala COPD use

GSK share price set for Monday watch after EU clears Nucala COPD use

7 February 2026
GSK shares closed Friday up 0.83% at a 52-week high after the EU approved Nucala for certain uncontrolled COPD patients. Insider filings showed chairman Jonathan Symonds bought 2,500 shares while executive David Redfern sold 100,000. The FTSE 100 rose 0.6%. Broker ratings on GSK remained mixed.
Go toTop